Corbevax (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Corbevax" in English language version.

refsWebsite

Global rank English rank

4^th place

4^th place

2^nd place

2^nd place

4web.archive.org

1^st place

1^st place

low place

low place

low place

low place

390^th place

227^th place

20^th place

30^th place

92^nd place

72^nd place

low place

low place

1semanticscholar.org

11^th place

8^th place

1indianexpress.com

60^th place

43^rd place

18^th place

17^th place

987^th place

560^th place

52^nd place

35^th place

1hindustantimes.com

71^st place

52^nd place

14^th place

14^th place

1washingtonpost.com

34^th place

27^th place

138^th place

95^th place

175^th place

137^th place

1deccanherald.com

516^th place

291^st place

1titosvodka.com

low place

low place

1theguardian.com

12^th place

11^th place

low place

low place

1indiatimes.com

17^th place

15^th place

1scientificamerican.com

896^th place

674^th place

archive.today

"A new coronavirus vaccine heading to India was developed by a small team in Texas. It expects nothing in return". The Washington Post. 30 December 2021. Archived from the original on 1 January 2022.

bbc.com

"Covovax and Corbevax: What we know about India's new Covid vaccines". BBC News. 28 December 2021.
"Covovax and Corbevax: What we know about India's new Covid vaccines". BBC News. 28 December 2021.

bcm.edu

Chui M (16 November 2020). "Biological E. Limited and Baylor COVID-19 vaccine begins clinical trial in India". Baylor College of Medicine.
Pathak D (13 May 2020). "Tito's Handmade Vodka gives $1M grant for COVID-19 vaccine". Baylor College of Medicine. Retrieved 29 January 2022.

cepi.net

"CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. 29 December 2020. Archived from the original on 29 December 2020. Retrieved 5 March 2021.

ctri.nic.in

"A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.
"A Prospective, multicentre, Phase II Seamlessly Followed by Phase III Clinical Study to Evaluate the Immunogenicity and Safety of Biological E's CORBEVAX Vaccine for Protection Against COVID-19 Disease When Administered to COVID-19-Negative Adult Subjects". ctri.nic.in. Clinical Trials Registry India. 5 June 2021. CTRI/2021/06/034014. Archived from the original on 5 June 2021.

deccanherald.com

"Corbevax as heterologous booster along wth [sic] Covishield more effective against Covid-19 variants: Research". Deccan Herald. 25 December 2022. Retrieved 19 June 2023.

doi.org

Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Nanishi E, Borriello F, O'Meara TR, McGrath ME, Saito Y, Haupt RE, et al. (January 2022). "An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice". Science Translational Medicine. 14 (629): eabj5305. doi:10.1126/scitranslmed.abj5305. PMC 10176044. PMID 34783582.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, et al. (August 2022). "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials". eBioMedicine. 83: 104217. doi:10.1016/j.ebiom.2022.104217. PMC 9372721. PMID 35970020.
Prakash S (April 2022). "Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants". Diabetes & Metabolic Syndrome. 16 (4). Elsevier BV: 102482. doi:10.1016/j.dsx.2022.102482. PMC 8990436. PMID 35427915. As per company claim, Corbevax showed over 90% effective (Table 1) against the original SARS CoV2 variant based on antibodies produced by the people who received the vaccine.
Dowling DJ, Levy O (August 2022). "A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations". Clinical Infectious Diseases. 75 (Suppl 1): S30 – S36. doi:10.1093/cid/ciac342. PMC 9129145. PMID 35512145.

dynavax.com

investors.dynavax.com

"Dynavax Awarded $17 Million Contract from National Institutes of Health" (Press release). Dynavax. 29 September 2008.

harvard.edu

hms.harvard.edu

Fliesler N (6 January 2022). "Another Angle of Attack". Harvard Medical School. Retrieved 23 June 2024.

hindustantimes.com

"Health ministry buys 300 mn doses of Biological-E's Covid vaccine in advance". Hindustan Times. 3 June 2021. Retrieved 4 June 2021.

indianexpress.com

Raghavan P (10 June 2021). "Explained: How is Biological E's Corbevax different?". The Indian Express. Retrieved 29 December 2021.

indiatimes.com

timesofindia.indiatimes.com

Bharadwaj S (5 June 2021). "Bio E's Corbevax may be India's cheapest vaccine at Rs 250 per dose". The Times of India.

livemint.com

Leo L (16 November 2020). "Biological E initiates human trials of vaccine". Mint.
Leo L (24 April 2021). "Biological E completes phase-2 covid vaccine trial, gets SEC nod for phase-3". mint.

ndtv.com

Achom D (28 December 2021). "India Clears 2 New Vaccines And Merck's Covid Pill". NDTV.com.

nih.gov

pubmed.ncbi.nlm.nih.gov

Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.
Nanishi E, Borriello F, O'Meara TR, McGrath ME, Saito Y, Haupt RE, et al. (January 2022). "An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice". Science Translational Medicine. 14 (629): eabj5305. doi:10.1126/scitranslmed.abj5305. PMC 10176044. PMID 34783582.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, et al. (August 2022). "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials". eBioMedicine. 83: 104217. doi:10.1016/j.ebiom.2022.104217. PMC 9372721. PMID 35970020.
Prakash S (April 2022). "Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants". Diabetes & Metabolic Syndrome. 16 (4). Elsevier BV: 102482. doi:10.1016/j.dsx.2022.102482. PMC 8990436. PMID 35427915. As per company claim, Corbevax showed over 90% effective (Table 1) against the original SARS CoV2 variant based on antibodies produced by the people who received the vaccine.
Dowling DJ, Levy O (August 2022). "A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations". Clinical Infectious Diseases. 75 (Suppl 1): S30 – S36. doi:10.1093/cid/ciac342. PMC 9129145. PMID 35512145.

ncbi.nlm.nih.gov

Nanishi E, Borriello F, O'Meara TR, McGrath ME, Saito Y, Haupt RE, et al. (January 2022). "An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice". Science Translational Medicine. 14 (629): eabj5305. doi:10.1126/scitranslmed.abj5305. PMC 10176044. PMID 34783582.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, et al. (August 2022). "Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials". eBioMedicine. 83: 104217. doi:10.1016/j.ebiom.2022.104217. PMC 9372721. PMID 35970020.
Prakash S (April 2022). "Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants". Diabetes & Metabolic Syndrome. 16 (4). Elsevier BV: 102482. doi:10.1016/j.dsx.2022.102482. PMC 8990436. PMID 35427915. As per company claim, Corbevax showed over 90% effective (Table 1) against the original SARS CoV2 variant based on antibodies produced by the people who received the vaccine.
Dowling DJ, Levy O (August 2022). "A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations". Clinical Infectious Diseases. 75 (Suppl 1): S30 – S36. doi:10.1093/cid/ciac342. PMC 9129145. PMID 35512145.

npr.org

Palca J (31 August 2022). "Whatever happened to the new no patent covid vaccine touted as a global game changer".
"A Texas team comes up with a COVID vaccine that could be a global game changer". NPR.org. Retrieved 15 January 2022.

scientificamerican.com

Hotez PJ, Bottazzi ME (30 December 2021). "A COVID Vaccine for All". Scientific American. Archived from the original on 30 December 2021. Retrieved 2 January 2022.

semanticscholar.org

api.semanticscholar.org

Hotez PJ, Bottazzi ME (January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. PMID 34637324. S2CID 238747462.

theguardian.com

Salam E (15 January 2022). "Texas scientists' new Covid-19 vaccine is cheaper, easier to make and patent-free". the Guardian. Retrieved 13 August 2022.

thehindu.com

"Coronavirus | Biological E gets nod to start Phase III trials of COVID-19 vaccine". The Hindu. 24 April 2021.

theprint.in

Basu N (25 April 2021). "US assures export of raw materials to India for Covid vaccines as Doval speaks to Sullivan". ThePrint.

titosvodka.com

"Supporting COVID-19 Research". Tito's Vodka. 13 May 2020. Retrieved 29 January 2022.

vice.com

"Open-Source Vaccines Got More Funding From Tito's Vodka Than the Government". www.vice.com. 11 January 2022. Retrieved 25 January 2022.

washingtonpost.com

"A new coronavirus vaccine heading to India was developed by a small team in Texas. It expects nothing in return". The Washington Post. 30 December 2021. Archived from the original on 1 January 2022.

web.archive.org

"A prospective open label randomised phase-I seamlessly followed by phase-II study to assess the safety, reactogenicity and immunogenicity of Biological E's novel Covid-19 vaccine containing Receptor Binding Domain of SARS-CoV-2 for protection against Covid-19 disease when administered intramuscularly in a two dose schedule (0, 28D) to healthy volunteers". ctri.nic.in. Clinical Trials Registry India. 13 January 2021. CTRI/2020/11/029032. Archived from the original on 12 November 2020.
"CEPI partners with Biological E Limited to advance development and manufacture of COVID-19 vaccine candidate". cepi.net. CEPI. 29 December 2020. Archived from the original on 29 December 2020. Retrieved 5 March 2021.
"A Prospective, multicentre, Phase II Seamlessly Followed by Phase III Clinical Study to Evaluate the Immunogenicity and Safety of Biological E's CORBEVAX Vaccine for Protection Against COVID-19 Disease When Administered to COVID-19-Negative Adult Subjects". ctri.nic.in. Clinical Trials Registry India. 5 June 2021. CTRI/2021/06/034014. Archived from the original on 5 June 2021.
Hotez PJ, Bottazzi ME (30 December 2021). "A COVID Vaccine for All". Scientific American. Archived from the original on 30 December 2021. Retrieved 2 January 2022.